| LBCTR2021014651 | 000000 | Managing Endothelial Dysfunction in COVID-19: A Randomized Clinical Trial at the Lebanese American University Medical Center- Rizk Hospital | Managing Endothelial Dysfunction in COVID-19: A Randomized Clinical Trial at the Lebanese American University Medical Center- Rizk Hospital | Interventional | Pending | 07/02/2021 |
| LBCTR2020063513 | GBT440-038 | Open-Label Extension of Voxelotor | An Open-Label Extension Study of Voxelotor Administered Orally to Participants with Sickle Cell Disease Who Have Participated in Voxelotor Clinical Trials | Interventional | Pending | 12/06/2020 |
| LBCTR2024065610 | CAIN457C22301E1 | Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR) | A Multi-center, Open-label Extension Study of Subcutaneous Secukinumab to Evaluate the Long-term Safety and Tolerability in Polymyalgia Rheumatica (PMR) | Interventional | Pending | 14/06/2024 |
| LBCTR2019020189 | CICL670FIC05 | Open-label, Multicenter, Single Arm, Phase II Study Assessing Treatment Patient Preference for New Deferasirox Formulation (Film-coated Tablet) Compared to the Reference Deferasirox Dispersible Tablet Formulation | Open-label, Multicenter, Single Arm, Phase II Study Assessing Treatment Patient Preference for New Deferasirox Formulation (Film-coated Tablet) Compared to the Reference Deferasirox Dispersible Tablet Formulation | Interventional | Complete | 06/02/2019 |
| LBCTR2023055223 | RLY5016-208p | Patiromer for treatment of hyperkalaemia in children from birth to <6 years of age | A 2-Part, Open-Label, Phase 2, Multiple Dose Study to Evaluate the Pharmacodynamic Effects, Safety, and Tolerability of Patiromer in Children under 6 Years of Age with Hyperkalaemia (EMERALD 2) | Interventional | Other | 14/12/2022 |
| LBCTR2023125487 | LAU.SOP.ER1.14/Sep/2022 | Pharmacist-Led Medication Reconciliation Upon Discharge from the Orthopedic Surgery Department | Pharmacist-Led Medication Reconciliation Upon Discharge from the Orthopedic Surgery Department: An Interventional Randomized Controlled Trial | Interventional | Complete | 19/12/2023 |
| LBCTR2022095104 | RBSC2161 | Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients With Sickle Cell Disease | A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Characterize the Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients With Sickle Cell Disease | Interventional | Complete | 27/07/2022 |
| LBCTR2020043435 | DCR-PHXC-201 | Phase 2 Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of DCR-PHXC Solution for Injection (subcutaneous use) in Patients with Primary Hyperoxaluria | Phase 2 Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of DCR-PHXC Solution for Injection (subcutaneous use) in Patients with Primary Hyperoxaluria | Interventional | Complete | 19/03/2020 |
| LBCTR2021024523 | GC1801 | Phase 3 study to evaluate the efficacy and safety of human plasma-derived fibrinogen concentrate (FIB Grifols) in subjects with congenital afibrinogenaemia and severe hypofibrinogenemia | A prospective, multicenter, open-label, single-arm study to evaluate the efficacy and safety of human plasma-derived fibrinogen concentrate (FIB Grifols) in subjects with congenital afibrinogenaemia and severe hypofibrinogenemia requiring either ondemand treatment for acute bleeding or surgical prophylaxis | Interventional | Pending | 14/07/2020 |
| LBCTR2019060201 | CPDR001X2101 | Phase I/II Study of PDR001 in Patients With Advanced Malignancies | Open Label Multicenter Phase I/II Study of the Safety and Efficacy of PDR001 Administered to Patients With Advanced Malignancies | Interventional | Complete | 20/02/2019 |